{"id":71431,"date":"2026-05-20T11:00:00","date_gmt":"2026-05-20T11:00:00","guid":{"rendered":"https:\/\/medsbase.com\/aicar-acadesine\/"},"modified":"2026-10-15T10:33:56","modified_gmt":"2026-10-15T10:33:56","slug":"aicar-acadesine","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-br\/product\/aicar-acadesine\/","title":{"rendered":"AICAR (Acadesina \/ AICA-Ribos\u00eddeo)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 AICAR?<\/h3>\n<p style=\"margin: 0;\"><strong>AICAR<\/strong> (Acadesine \/ AICA-Ribos\u00eddeo \/ 5-aminoimidazol-4-carboxamida-1-\u03b2-D-ribofuranos\u00eddeo, CAS 2627-69-2) \u00e9 a pequena mol\u00e9cula can\u00f4nica <strong>Ativador de AMPK (prote\u00edna quinase ativada por AMP)<\/strong> used in metabolic, exercise-physiology, muscle, and cancer studies. AICAR is the cell-permeable riboside; once inside cells it is phosphorylated by adenosine kinase to the active nucleotide <strong>ZMP<\/strong> (5-aminoimidazole-4-carboxamide ribonucleotide), an AMP-mimetic that allosterically activates AMPK. Activated AMPK drives insulin-independent glucose uptake into skeletal muscle, increases fatty-acid oxidation, suppresses hepatic gluconeogenesis and de-novo lipogenesis, and inhibits mTORC1 \u2014 the canonical &#8220;exercise-in-a-pill&#8221; pharmacology. Supplied as lyophilized powder (\u226599% HPLC) for clinical studies use only. <em>N\u00e3o \u00e9 um pept\u00eddeo.<\/em><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que voc\u00ea obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-br\/reviews\/\">\ud83d\udce6 Cada pedido \u00e9 coberto pela nossa<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Todo pedido \u00e9 coberto pelo nosso <a href=\"https:\/\/medsbase.com\/pt-br\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Reenvio Garantido<\/strong><\/a> \u2014 se sua encomenda n\u00e3o chegar em 20 dias \u00fateis, n\u00f3s a reenviamos.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Classe do Composto<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">An\u00e1logo de nucleos\u00eddeo de purina de pequena mol\u00e9cula; mimetizador de AMP perme\u00e1vel \u00e0s c\u00e9lulas; ativador de AMPK; <em>n\u00e3o \u00e9 um pept\u00eddeo<\/em><\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Nome Qu\u00edmico<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">5-Aminoimidazol-4-carboxamida-1-\u03b2-D-ribofuranos\u00eddeo (sin\u00f4nimos: Acadesine, AICA-Ribos\u00eddeo, NSC 105823, Z-Ribos\u00eddeo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2627-69-2<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>F\u00f3rmula Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>9<\/sub>H<sub>14<\/sub>N<sub>4<\/sub>O<sub>5<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">258,23 g\/mol<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Mecanismo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">O ribos\u00eddeo AICA perme\u00e1vel \u00e0s c\u00e9lulas \u00e9 captado por transportadores de adenosina e fosforilado pela adenosina quinase para formar o monofosfato intracelular ativo <strong>ZMP<\/strong> (5-aminoimidazol-4-carboxamida ribonucleot\u00eddeo). O ZMP imita o AMP no dom\u00ednio Bateman da subunidade \u03b3 da AMPK, produzindo ativa\u00e7\u00e3o alost\u00e9rica da AMPK independentemente de altera\u00e7\u00f5es na rela\u00e7\u00e3o celular AMP:ATP. A AMPK ativada ent\u00e3o impulsiona o programa de comuta\u00e7\u00e3o metab\u00f3lica a jusante (catabolismo \u2191, anabolismo \u2193).<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Sequ\u00eancia<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">n\/a (ribonucleos\u00eddeo de purina de pequena mol\u00e9cula \u2014 n\u00e3o \u00e9 um pept\u00eddeo)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilized white-to-off-white crystalline powder; single-use vials<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (verificado por HPLC, COA sob solicita\u00e7\u00e3o)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Sol\u00favel em \u00e1gua (~50 mg\/mL com aquecimento suave e agita\u00e7\u00e3o), PBS e DMSO (estoque \u2265100 mM). Solu\u00e7\u00f5es aquosas podem requerer breve aquecimento a 37 \u00b0C para dissolu\u00e7\u00e3o completa. Solu\u00e7\u00f5es de trabalho para cultura de c\u00e9lulas s\u00e3o tipicamente preparadas a 0,5\u20132 mM em meio de crescimento.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C para estoque de trabalho de curto prazo; \u221220 \u00b0C para armazenamento de longo prazo de frascos n\u00e3o abertos (est\u00e1vel \u226536 meses a \u221220 \u00b0C). Solu\u00e7\u00f5es aquosas reconstitu\u00eddas: 2\u20138 \u00b0C, usar em ~30 dias. Estoques em DMSO: \u221220 \u00b0C, uso \u00fanico ap\u00f3s descongelamento. Proteger da exposi\u00e7\u00e3o prolongada \u00e0 luz. Evitar ciclos repetidos de congelamento-descongelamento de solu\u00e7\u00f5es de trabalho.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 AICAR?<\/h2>\n<p><strong>AICAR<\/strong> (5-Aminoimidazol-4-carboxamida-1-\u03b2-D-ribofuranos\u00eddeo, tamb\u00e9m conhecido como Acadesina, AICA-Ribos\u00eddeo, NSC 105823 ou Z-Ribos\u00eddeo; CAS 2627-69-2) \u00e9 um an\u00e1logo de ribonucleos\u00eddeo de purina de pequena mol\u00e9cula e a ferramenta farmacol\u00f3gica mais citada para ativa\u00e7\u00e3o <strong>prote\u00edna quinase ativada por AMP (AMPK)<\/strong> in cell-culture, primary-cell, and rodent in-vivo studies. It is <em>n\u00e3o \u00e9 um pept\u00eddeo<\/em> \u2014 \u00e9 um ribonucleos\u00eddeo sint\u00e9tico com a f\u00f3rmula molecular C<sub>9<\/sub>H<sub>14<\/sub>N<sub>4<\/sub>O<sub>5<\/sub> and a molecular weight of 258.23 g\/mol. MedsBase stocks it in the same lyophilized-vial format as our peptide catalogue for convenience of reconstitution and dosing in mixed-protocol AMPK \/ metabolic \/ mitochondrial studies. AICAR was originally developed in the 1990s by Acadesine Inc. (later Schering-Plough) as a candidate cardioprotective agent for coronary artery bypass surgery \u2014 the compound completed Phase III trials but did not gain regulatory approval. Its pharmacological utility, however, has only expanded since: AICAR is now the standard reference compound for AMPK activation in published studies, and the AMPK pathway it engages has been implicated in nearly every major area of metabolic biology \u2014 insulin sensitivity, type-2 diabetes, fatty-acid oxidation, exercise physiology, muscle hypertrophy \/ atrophy, mitochondrial biogenesis, cancer metabolism, autophagy, and ageing. In published studies AICAR is described as an &#8220;exercise mimetic&#8221; because chronic administration in sedentary mice has been reported to drive a skeletal-muscle gene-expression signature, mitochondrial-biogenesis programme, and endurance-performance phenotype that broadly mimics the effects of voluntary wheel running \u2014 the original 2008 Narkar et\u00a0al. publication in <em>C\u00e9lula<\/em> (\u201cAMPK e PPAR\u03b4 Agonistas S\u00e3o Mim\u00e9ticos do Exerc\u00edcio\u201d) \u00e9 o artigo mais citado nesta \u00e1rea. O AICAR tamb\u00e9m est\u00e1 na Lista de Subst\u00e2ncias Proibidas da WADA (classe S4.5, Moduladores Metab\u00f3licos) e \u00e9 proibido no esporte a qualquer momento devido a esse potencial de melhoria de desempenho. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Ativa\u00e7\u00e3o Celular da AMPK via ZMP<\/h2>\n<p>O mecanismo do AICAR \u00e9 o mais caracterizado de qualquer ativador farmacol\u00f3gico da AMPK:<\/p>\n<ul>\n<li><strong>Entrada celular via transportadores de adenosina<\/strong> \u2014 O AICAR (o ribos\u00eddeo) \u00e9 biologicamente inerte por si s\u00f3. Ele \u00e9 captado pelas c\u00e9lulas atrav\u00e9s dos mesmos transportadores de adenosina equilibrativos e concentrativos (ENT1, ENT2, CNT2, CNT3) que movem a adenosina end\u00f3gena e outros nucleos\u00eddeos de purina atrav\u00e9s da membrana plasm\u00e1tica. A distribui\u00e7\u00e3o tecidual e a cin\u00e9tica de concentra\u00e7\u00e3o in vivo s\u00e3o governadas por esses transportadores.<\/li>\n<li><strong>Fosforila\u00e7\u00e3o intracelular para ZMP pela adenosina quinase<\/strong> \u2014 Uma vez intracelular, o AICAR \u00e9 fosforilado pela <strong>adenosina quinase (AK)<\/strong> on its 5\u2032-hydroxyl, generating the active metabolite ZMP (5-aminoimidazole-4-carboxamide ribonucleotide). ZMP is the immediate AMP analogue and is the species that actually engages AMPK. Adenosine kinase activity is therefore the rate-limiting step for AICAR pharmacology in any given tissue \u2014 protocols that use AK-deficient cells or AK inhibitors confirm that ZMP, not AICAR itself, is the active species.<\/li>\n<li><strong>Ativa\u00e7\u00e3o alost\u00e9rica da AMPK na subunidade \u03b3<\/strong> \u2014 O ZMP se liga aos mesmos s\u00edtios Bateman-dom\u00ednio CBS na subunidade \u03b3 da AMPK que o AMP end\u00f3geno ocupa em condi\u00e7\u00f5es de baixa energia. A liga\u00e7\u00e3o do ZMP produz tr\u00eas efeitos alost\u00e9ricos convergentes na AMPK: (1) estimula\u00e7\u00e3o alost\u00e9rica da atividade catal\u00edtica, (2) prote\u00e7\u00e3o da fosforila\u00e7\u00e3o da Thr172 na subunidade \u03b1 da AMPK contra desfosforila\u00e7\u00e3o pela PP2C, e (3) aumento da fosforila\u00e7\u00e3o da Thr172 pelas quinases upstream LKB1 e CaMKK2. O resultado l\u00edquido \u00e9 uma ativa\u00e7\u00e3o sustentada e de alto n\u00edvel da AMPK que \u00e9 independente de mudan\u00e7as na raz\u00e3o celular real de AMP:ATP.<\/li>\n<li><strong>Interruptor metab\u00f3lico downstream \u2014 upregula\u00e7\u00e3o catab\u00f3lica<\/strong> \u2014 Activated AMPK phosphorylates a large set of metabolic effectors that drive the catabolic \/ energy-generating programme: ACC (acetyl-CoA carboxylase, on Ser79 and Ser212) \u2014 relieving malonyl-CoA inhibition of CPT-I and allowing long-chain fatty acids into the mitochondria for \u03b2-oxidation; HSL (hormone-sensitive lipase) \u2014 increasing adipocyte lipolysis; TBC1D1 \u2014 driving insulin-independent GLUT4 translocation and glucose uptake into skeletal muscle; PGC-1\u03b1 \u2014 driving mitochondrial biogenesis. The skeletal-muscle glucose-uptake effect is the most-cited functional readout in AMPK studies.<\/li>\n<li><strong>Interruptor metab\u00f3lico downstream \u2014 supress\u00e3o anab\u00f3lica<\/strong> \u2014 A AMPK ativada suprime simultaneamente vias anab\u00f3licas \/ consumidoras de energia: a fosforila\u00e7\u00e3o de TSC2 e Raptor inibe a mTORC1, suprimindo a s\u00edntese proteica e desencadeando a autofagia; a fosforila\u00e7\u00e3o da HMG-CoA redutase suprime a s\u00edntese de colesterol; a fosforila\u00e7\u00e3o do SREBP1c suprime a lipog\u00eanese hep\u00e1tica de novo; a fosforila\u00e7\u00e3o da PFKFB3 e ACC suprime a s\u00edntese de glicog\u00eanio e \u00e1cidos graxos. O interruptor combinado catab\u00f3lico-up \/ anab\u00f3lico-down \u00e9 a farmacologia can\u00f4nica da AMPK.<\/li>\n<\/ul>\n<p>The pharmacokinetic profile of AICAR is broadly favourable for use \u2014 oral bioavailability is modest but workable, intraperitoneal administration in rodents produces reliable systemic exposure within 30 minutes, and the plasma half-life of the parent riboside is on the order of 90 minutes (the half-life of the intracellular ZMP metabolite is longer, sustaining AMPK activation for several hours after a single bolus dose). Typical in-vivo rodent protocols use 250\u2013500\u00a0mg\/kg administered IP daily; high doses (1\u00a0g\/kg) have been used in some published muscle-physiology studies. In-vitro cell culture work typically uses 0.5\u20132\u00a0mM in growth medium. <\/p>\n<h2>Published Evidence<\/h2>\n<p>AICAR is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Farmacologia da AMPK \u2014 o ativador de refer\u00eancia can\u00f4nico<\/strong> \u2014 by far the most-cited small-molecule AMPK activator in the published literature; standard tool compound for any new AMPK-pathway studies; reference compound against which all newer direct AMPK activators (A769662, MK-8722, PF-739, O304, the metformin class) are benchmarked<\/li>\n<li><strong>Sensibilidade \u00e0 insulina e capta\u00e7\u00e3o de glucose no m\u00fasculo esquel\u00e9tico<\/strong> \u2014 AICAR drives insulin-independent GLUT4 translocation and glucose uptake into skeletal muscle via the AMPK-TBC1D1 axis; widely used in studies on type-2 diabetes, insulin-resistance reversal, and skeletal-muscle metabolic flexibility<\/li>\n<li><strong>Exercise mimetic and endurance studies<\/strong> \u2014 o framework de Narkar et al. (2008, \u201cAMPK and PPAR\u03b4 Agonists Are Exercise Mimetics\u201d) continua sendo o artigo mais citado sobre AICAR; protocolos publicados em roedores documentam aumento da resist\u00eancia, convers\u00e3o de fibras de contra\u00e7\u00e3o lenta (Tipo I) e melhora da capacidade oxidativa ap\u00f3s 4 semanas de dosagem com AICAR em camundongos sedent\u00e1rios, <em>C\u00e9lula<\/em>) O framework \u201cAMPK e PPAR\u03b4 Agonistas S\u00e3o Mimetizadores de Exerc\u00edcio\u201d continua sendo o artigo mais citado sobre AICAR; protocolos publicados em roedores documentam aumento de resist\u00eancia, convers\u00e3o de fibras de contra\u00e7\u00e3o lenta (Tipo I) e melhora na capacidade oxidativa ap\u00f3s 4 semanas de dosagem de AICAR em camundongos sedent\u00e1rios<\/li>\n<li><strong>Supress\u00e3o da gliconeog\u00eanese e lipog\u00eanese hep\u00e1ticas<\/strong> \u2014 AICAR suppresses hepatic glucose output via AMPK-mediated phosphorylation of transcriptional co-activators (CRTC2, HNF4\u03b1); also suppresses hepatic de-novo lipogenesis via SREBP1c phosphorylation; used in non-alcoholic fatty liver disease (NAFLD) and metabolic-dysfunction-associated steatohepatitis (MASH) preclinical studies<\/li>\n<li><strong>Fatty-acid oxidation studies<\/strong> \u2014 O AICAR fosforila a ACC, alivia a inibi\u00e7\u00e3o da CPT-I pelo malonil-CoA e direciona \u00e1cidos graxos de cadeia longa para as mitoc\u00f4ndrias para \u03b2-oxida\u00e7\u00e3o; a interven\u00e7\u00e3o farmacol\u00f3gica can\u00f4nica para regular positivamente a oxida\u00e7\u00e3o de \u00e1cidos graxos em hepat\u00f3citos prim\u00e1rios, cardiomi\u00f3citos e miotubos de m\u00fasculo esquel\u00e9tico<\/li>\n<li><strong>Cancer metabolism studies<\/strong> \u2014 many cancer cells display elevated lipogenesis (via SREBP1c) and elevated mTORC1 signalling; AICAR suppresses both via AMPK activation and has been investigated in published studies on acute lymphoblastic leukaemia (the historical original indication for Acadesine), prostate cancer, breast cancer, and other tumour models<\/li>\n<li><strong>Autophagy and mTORC1-inhibition studies<\/strong> \u2014 AICAR triggers autophagy via dual phosphorylation of TSC2 (Ser1387) and Raptor (Ser792), both of which inhibit mTORC1; used as a pharmacological intervention in autophagy-induction studies alongside rapamycin and starvation models<\/li>\n<li><strong>Mitochondrial biogenesis studies<\/strong> \u2014 O AICAR impulsiona a express\u00e3o e atividade de PGC-1\u03b1, aumentando a biog\u00eanese mitocondrial em m\u00fasculo esquel\u00e9tico e tecido adiposo marrom; complementar a <a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a> (pept\u00eddeo ativador de AMPK derivado mitocondrial) em protocolos que investigam redund\u00e2ncia da via da AMPK<\/li>\n<li><strong>Cardioprotection studies<\/strong> \u2014 the original clinical indication; AICAR has been used in ischaemia-reperfusion injury models and the cardiac-surgery cardioprotection paradigm; preclinical studies continues despite Phase III not gaining approval<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre AMPK \/ NAD<sup>+<\/sup> \/ metabolic-axis compounds in this catalogue, see <a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a> (inibidor de NNMT; abordagem complementar de preserva\u00e7\u00e3o de precursores de NAD), <a href=\"https:\/\/medsbase.com\/pt-br\/5-amino-1mq\/\">5-Amino-1MQ<\/a> (Inibidor de NNMT; NAD complementar<sup>+<\/sup>(transporte mitocondrial de \u00e1cidos graxos de cadeia longa). Navegue pelo, <a href=\"https:\/\/medsbase.com\/pt-br\/nad\/\">NAD<sup>+<\/sup><\/a> (coenzima dinucleot\u00eddica oxidada, substrato central de transporte de el\u00e9trons), e <a href=\"https:\/\/medsbase.com\/pt-br\/l-carnitine\/\">L-Carnitina<\/a> (transporte mitocondrial de \u00e1cidos graxos de cadeia longa). Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-br\/peptides\/\">peptides &amp; compounds catalog<\/a> para compostos relacionados, ou consulte os <a href=\"https:\/\/medsbase.com\/pt-br\/best-longevity-peptides\/\">longevity compounds<\/a> e <a href=\"https:\/\/medsbase.com\/pt-br\/best-peptides-for-fat-loss\/\">fat-loss peptides<\/a> hubs. <\/p>\n<h2>Concentra\u00e7\u00f5es e Dosagens Dispon\u00edveis<\/h2>\n<p>MedsBase stocks AICAR in a single lyophilized vial size calibrated to typical in-vivo and high-throughput in-vitro protocols. The vial is available in 10-vial, 20-vial, or 30-vial pack formats:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Dosagem do Frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de Uso T\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos de Embalagem<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>50 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 single-cohort in-vivo rodent dosing (250\u2013500\u00a0mg\/kg IP daily for 2\u20134 weeks covers a 30-g mouse cohort with one 50\u00a0mg vial per ~2\u20133 doses), high-throughput in-vitro AMPK-activation panels (0.5\u20132\u00a0mM working concentrations), reconstitution-and-dose-titration work, primary-hepatocyte \/ myotube fatty-acid-oxidation panels<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The 50\u00a0mg vial format provides a convenient dosing unit for most published in-vivo rodent protocols and supports the 0.5\u20132\u00a0mM working concentrations used in cell-culture AMPK-activation studies. The 30-vial pack is the more economical purchase per-mg for extended-cycle or large-cohort protocols (4\u20138 week chronic dosing, multi-cohort exercise-mimetic studies). Users should determine specific dose ranges from peer-reviewed literature appropriate to the protocol. <\/p>\n<h2>Como eles se comparam \u2014 AICAR vs MOTS-c<\/h2>\n<p>AICAR e <a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a> are the two most-studied AMPK-activating compounds in this catalogue, and they target the AMPK pathway via mechanistically distinct routes. AICAR is a small-molecule cell-permeable AMP-mimetic that drives AMPK activation directly at the \u03b3-subunit. MOTS-c is a mitochondrial-derived 16-amino-acid peptide that translocates to the nucleus under metabolic stress and activates AMPK indirectly through a folate-pathway \/ methionine-cycle intermediate (AICAR-like increase in cellular AICAR \/ ZMP levels). The two compounds are mechanistically complementary in published combination studies, and the comparison illustrates one of the most-studied &#8220;small-molecule vs peptide&#8221; dyads in AMPK biology. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">AICAR<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">MOTS-c<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Classe qu\u00edmica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pequena mol\u00e9cula ribonucleos\u00eddica de purina (mimetizador de AMP perme\u00e1vel \u00e0s c\u00e9lulas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Pept\u00eddeo mitocondrial de 16 res\u00edduos (via MTHFD2L\/mecanismo de ac\u00famulo semelhante ao AICAR)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Peso molecular<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">258,23 g\/mol<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~2.174 g\/mol (pept\u00eddeo de 16 res\u00edduos)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Via de ativa\u00e7\u00e3o da AMPK<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Direta \u2014 fosforilado para ZMP intracelularmente, liga-se ao dom\u00ednio Bateman da subunidade \u03b3 da AMPK (mimetizador de AMP)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Indireta \u2014 perturba o ciclo do folato\/metionina, eleva os n\u00edveis celulares de AICAR\/ZMP, ativa a AMPK atrav\u00e9s do mesmo s\u00edtio alost\u00e9rico da subunidade \u03b3<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Best-studied studies focus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Mimetizador de exerc\u00edcio, sensibilidade \u00e0 insulina, gliconeog\u00eanese hep\u00e1tica, metabolismo do c\u00e2ncer, autofagia, biog\u00eanese mitocondrial<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sensibilidade \u00e0 insulina, biologia mitocondrial, decl\u00ednio metab\u00f3lico relacionado \u00e0 idade, longevidade, farmacologia do eixo pept\u00eddico<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Estabilidade plasm\u00e1tica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~90 min de meia-vida plasm\u00e1tica (ribos\u00eddeo parental); ZMP intracelular mant\u00e9m o efeito por v\u00e1rias horas por dose em bolus<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short \u2014 minutes of plasma half-life unprotected; supports IP \/ SC dosing in studies<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose t\u00edpica<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">250\u2013500 mg\/kg IP diariamente em roedores (ocasionalmente 1 g\/kg em protocolos de fisiologia muscular); 0,5\u20132 mM em cultura celular<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0,5\u20135 mg\/kg IP\/SC em roedores<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Seletividade\/perfil de alvos fora do alvo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">N\u00e3o \u00e9 puramente seletivo \u2014 ZMP tamb\u00e9m afeta a sinaliza\u00e7\u00e3o de adenosina, frutose-1,6-bisfosfatase e AMP-desaminase em doses altas<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Seletividade de classe pept\u00eddica \u2014 menos efeitos documentados em receptores de pequenas mol\u00e9culas fora do alvo, mas a identidade do receptor permanece sob investiga\u00e7\u00e3o<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Status regulat\u00f3rio<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sem aprova\u00e7\u00e3o cl\u00ednica (Acadesina Fase III para CABG n\u00e3o obteve aprova\u00e7\u00e3o); Lista de Proibi\u00e7\u00f5es da WADA S4.5 (proibido no esporte em todos os momentos)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">No clinical approval; studies-only peptide<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For studies focused on direct, high-magnitude AMPK activation with the canonical small-molecule reference tool, AICAR is the standard compound. For studies focused on peptide-class AMPK activation, mitochondrial-derived signalling, or longevity-axis peptide pharmacology, <a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a> \u00e9 a ferramenta mais direcionada. Veja tamb\u00e9m <a href=\"https:\/\/medsbase.com\/pt-br\/5-amino-1mq\/\">5-Amino-1MQ<\/a> for NAD-axis precursor-sparing studies, <a href=\"https:\/\/medsbase.com\/pt-br\/ss-31-elamipretide\/\">SS-31 (Elamipretide)<\/a> for cardiolipin-binding mitochondrial-targeted studies, and <a href=\"https:\/\/medsbase.com\/pt-br\/nad\/\">NAD<sup>+<\/sup><\/a> para suplementa\u00e7\u00e3o direta do pool de NAD. <\/p>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 14px 18px; margin: 18px 0;\"><strong class=\"mb-bac-water-callout\">\ud83d\udca7 Precisa de \u00e1gua BAC?<\/strong> A reconstitui\u00e7\u00e3o de qualquer frasco liofilizado requer \u00e1gua bacteriost\u00e1tica est\u00e9ril. Combine este produto com nosso <a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 frasco multidose de 30 mL, preservado com 0,9% de \u00e1lcool benz\u00edlico, grau USP.<\/div>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138 \u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo, congele frascos n\u00e3o abertos a \u221220 \u00b0C (est\u00e1vel \u226536 meses a \u221220 \u00b0C; \u226512 meses a 2\u20138 \u00b0C). O AICAR liofilizado \u00e9 substancialmente mais est\u00e1vel do que a maioria dos pept\u00eddeos liofilizados porque o ribonucleos\u00eddeo de pequena mol\u00e9cula n\u00e3o possui liga\u00e7\u00f5es amida ou pontes dissulfeto para hidrolisar. Proteja da exposi\u00e7\u00e3o prolongada \u00e0 luz direta. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> para o frasco de 50 mg, injete 1,0 mL de \u00e1gua bacteriost\u00e1tica, \u00e1gua est\u00e9ril ou PBS est\u00e9ril na parede lateral do frasco \u2014 isso resulta em uma solu\u00e7\u00e3o estoque de trabalho de 50 mg\/mL (~193 mM). Para solu\u00e7\u00f5es estoque de trabalho mais dilu\u00eddas, 2,5 mL rendem 20 mg\/mL (~77 mM), e 5,0 mL rendem uma solu\u00e7\u00e3o estoque de trabalho de 10 mg\/mL (~39 mM). O AICAR dissolve-se rapidamente com agita\u00e7\u00e3o suave \u00e0 temperatura ambiente; um breve aquecimento a 37 \u00b0C acelera a dissolu\u00e7\u00e3o se cristais residuais de armazenamento a frio estiverem presentes. Para trabalhos de cultura de c\u00e9lulas in vitro, o DMSO tamb\u00e9m \u00e9 um solvente de reconstitui\u00e7\u00e3o adequado (estoque de at\u00e9 200 mM); dilua as solu\u00e7\u00f5es de trabalho em meio aquoso imediatamente antes do uso, visando uma concentra\u00e7\u00e3o final de 0,5\u20132 mM no meio de crescimento. Uma vez reconstitu\u00eddo em tamp\u00e3o aquoso, armazene o frasco a 2\u20138 \u00b0C e use-o dentro de 30 dias. Proteja da luz. Descarte se aparecer turva\u00e7\u00e3o, part\u00edculas ou mudan\u00e7a marcante de cor. <\/p>\n<h2>Perguntas Frequentes<\/h2>\n<h3>O AICAR \u00e9 um pept\u00eddeo?<\/h3>\n<p>N\u00e3o. O AICAR \u00e9 um an\u00e1logo de ribonucleos\u00eddeo de purina de pequena mol\u00e9cula (MW 258,23 g\/mol), <em>n\u00e3o<\/em> a peptide. We stock it in our studies-peptide catalogue alongside <a href=\"https:\/\/medsbase.com\/pt-br\/5-amino-1mq\/\">5-Amino-1MQ<\/a>, <a href=\"https:\/\/medsbase.com\/pt-br\/nad\/\">NAD<sup>+<\/sup><\/a> e <a href=\"https:\/\/medsbase.com\/pt-br\/l-carnitine\/\">L-Carnitina<\/a> because it serves a complementary role in mitochondrial \/ metabolic \/ AMPK-axis studies and is supplied in the same lyophilized vial format. The spec table Sequence row is marked &#8220;n\/a&#8221; for this reason. <\/p>\n<h3>Qual \u00e9 a diferen\u00e7a entre AICAR, Acadesina, AICA-Ribos\u00eddeo e ZMP?<\/h3>\n<p>AICAR, Acadesina, AICA-Ribos\u00eddeo, NSC 105823 e Z-Ribos\u00eddeo s\u00e3o <em>todos o mesmo composto<\/em> \u2014 cinco nomes diferentes para 5-aminoimidazol-4-carboxamida-1-\u03b2-D-ribofuranos\u00eddeo, o ribos\u00eddeo perme\u00e1vel \u00e0 c\u00e9lula (CAS 2627-69-2). <strong>ZMP<\/strong> is a different compound \u2014 the intracellular monophosphate (5-aminoimidazole-4-carboxamide ribonucleotide), generated by adenosine kinase from the riboside once it has entered the cell. ZMP is the actual AMP-mimetic that engages AMPK; the riboside itself (AICAR) is the cell-permeable pro-drug. Studies suppliers sell the riboside because it is cell-permeable; the monophosphate (ZMP) does not cross the plasma membrane. <\/p>\n<h3>Por que o AICAR \u00e9 chamado de \u201cmim\u00e9tico de exerc\u00edcio\u201d?<\/h3>\n<p>O artigo de Narkar et al. (2008) <em>C\u00e9lula<\/em> \u201cAMPK e PPAR\u03b4 Agonistas S\u00e3o Mim\u00e9ticos de Exerc\u00edcio\u201d relatou que 4 semanas de administra\u00e7\u00e3o de AICAR em camundongos sedent\u00e1rios (500 mg\/kg\/d IP) produziram uma assinatura de express\u00e3o g\u00eanica no m\u00fasculo esquel\u00e9tico, um perfil de biog\u00eanese mitocondrial, uma mudan\u00e7a no tipo de fibra em dire\u00e7\u00e3o \u00e0s fibras oxidativas de contra\u00e7\u00e3o lenta (Tipo I) e um fen\u00f3tipo de desempenho de resist\u00eancia que imitou amplamente os efeitos da corrida volunt\u00e1ria em roda em camundongos n\u00e3o tratados. A frase \u201cexerc\u00edcio em uma p\u00edlula\u201d vem deste artigo. O AICAR est\u00e1 na Lista de Subst\u00e2ncias Proibidas da WADA em parte devido a esses achados de melhora de desempenho. <\/p>\n<h3>What published dose ranges have been used in mouse and rat studies?<\/h3>\n<p>The most-cited mouse-protocol dose is 250\u2013500\u00a0mg\/kg IP daily, administered for 2\u20134 weeks. The endurance-phenotype Narkar et\u00a0al. protocol used 500\u00a0mg\/kg\/d IP for 4 weeks. Higher doses (up to 1\u00a0g\/kg) have been used in some muscle-physiology studies. Rat protocols are similar (250\u2013500\u00a0mg\/kg IP). In-vitro cell-culture work typically uses 0.5\u20132\u00a0mM AICAR in growth medium. Users should consult primary literature (Narkar et\u00a0al. 2008; Corton et\u00a0al. 1995 original AMPK-activation paper; Merrill et\u00a0al. 1997 skeletal-muscle glucose-uptake paper) for species-, model-, and endpoint-specific dosing guidance. <\/p>\n<h3>Qual \u00e9 o status regulat\u00f3rio do AICAR na WADA?<\/h3>\n<p>AICAR \/ Acadesine is listed on the World Anti-Doping Agency (WADA) Prohibited List under class S4.5 (Hormone and Metabolic Modulators) and is prohibited in sport at all times \u2014 both in-competition and out-of-competition. The basis is the exercise-mimetic endurance-phenotype finding. Users conducting human-subject studies with AICAR need to be aware of this status (in addition to regulatory requirements for any unapproved drug). For clinical in-vitro and rodent in-vivo studies the WADA status is informational only. <\/p>\n<h3>Como o AICAR se compara \u00e0 metformina como um ativador da AMPK?<\/h3>\n<p>Tanto o AICAR quanto a metformina ativam a AMPK, mas por meio de rotas upstream completamente diferentes. O AICAR (ap\u00f3s convers\u00e3o intracelular em ZMP) \u00e9 um <em>diretamente<\/em> mim\u00e9tico de AMP que se liga ao dom\u00ednio Bateman da subunidade \u03b3 da AMPK. A metformina \u00e9 um <em>indireto<\/em> ativador da AMPK \u2014 ela inibe o complexo I mitocondrial, o que reduz o ATP e aumenta a raz\u00e3o AMP:ATP, ativando secundariamente a AMPK por meio do mecanismo natural de liga\u00e7\u00e3o ao AMP. Os dois compostos, portanto, exploram diferentes camadas da via da AMPK: o AICAR\/ZMP ignora a necessidade de estresse energ\u00e9tico real, enquanto a metformina envolve o ramo natural de detec\u00e7\u00e3o de energia. Novos ativadores diretos da AMPK (A769662, MK-8722, PF-739, O304) se ligam a um terceiro s\u00edtio (o bolso alost\u00e9rico da subunidade \u03b2\/ADaM) e oferecem melhor seletividade de isoforma do que o AICAR ou a metformina. <\/p>\n<h3>O AICAR pode ser combinado com MOTS-c, NAD<sup>+<\/sup>, or 5-Amino-1MQ in protocols?<\/h3>\n<p>Yes \u2014 the four compounds target overlapping but mechanistically distinct nodes of mitochondrial \/ AMPK \/ NAD-axis biology and are commonly combined in studies that aims to dissect direct AMPK activation (AICAR) from peptide-class AMPK activation (<a href=\"https:\/\/medsbase.com\/pt-br\/mots-c\/\">MOTS-c<\/a>), a partir de poupan\u00e7a de precursores de NAD (<a href=\"https:\/\/medsbase.com\/pt-br\/5-amino-1mq\/\">5-Amino-1MQ<\/a>), a partir de suplementa\u00e7\u00e3o direta do pool de NAD (<a href=\"https:\/\/medsbase.com\/pt-br\/nad\/\">NAD<sup>+<\/sup><\/a>). Reconstitua cada um separadamente primeiro para estabelecer estabilidade e precis\u00e3o de concentra\u00e7\u00e3o, depois combine imediatamente antes do uso, em vez de armazenar frascos reconstitu\u00eddos em conjunto. As combina\u00e7\u00f5es mais publicadas s\u00e3o AICAR + metformina (ativa\u00e7\u00e3o dupla de AMPK, ramifica\u00e7\u00f5es ascendentes diferentes) e AICAR + rapamicina (inibi\u00e7\u00e3o dupla de mTORC1, mecanismos diferentes). <\/p>\n<h3>Por que a Acadesina n\u00e3o obteve aprova\u00e7\u00e3o cl\u00ednica?<\/h3>\n<p>Acadesine (the clinical-trial name for AICAR) completed two large Phase III trials for cardioprotection in coronary artery bypass surgery (CABG) in the 1990s. The trials did not demonstrate statistically significant reductions in the primary composite endpoint (myocardial infarction, stroke, cardiovascular death), and the development programme was discontinued. AICAR remains a tool compound rather than an approved drug, although a number of academic groups have continued to investigate the cardioprotection paradigm and the broader AMPK-pathway pharmacology. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Compounds for AMPK and Metabolic Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-br\/mots-c\/\"><strong>MOTS-c<\/strong><\/a> \u2014 Pept\u00eddeo ativador de AMPK derivado mitocondrial \u2014 an\u00e1logo pept\u00eddico mecanicista mais pr\u00f3ximo<\/li>\n<li><a href=\"\/pt-br\/5-amino-1mq\/\"><strong>5-Amino-1MQ<\/strong><\/a> \u2014 Inibidor seletivo de NNMT \u2014 abordagem complementar de poupan\u00e7a de precursores de NAD<\/li>\n<li><a href=\"\/pt-br\/nad\/\"><strong>NAD\u207a<\/strong><\/a> \u2014 Oxidised dinucleotide coenzyme \u2014 direct NAD-pool supplementation studies<\/li>\n<li><a href=\"\/pt-br\/ss-31-elamipretide\/\"><strong>SS-31 (Elamipretide)<\/strong><\/a> \u2014 Pept\u00eddeo mitocondrial direcionado com liga\u00e7\u00e3o a cardiolipina<\/li>\n<li><a href=\"\/pt-br\/l-carnitine\/\"><strong>L-Carnitina<\/strong><\/a> \u2014 Transportador mitocondrial de \u00e1cidos graxos de cadeia longa \u2014 mol\u00e9cula pequena complementar<\/li>\n<li><a href=\"\/pt-br\/bac-water\/\"><strong>\u00c1gua BAC (\u00c1gua Bacteriost\u00e1tica)<\/strong><\/a> \u2014 Necess\u00e1rio para reconstituir qualquer frasco liofilizado \u2014 diluente est\u00e9ril, preservado com 0,9% de \u00e1lcool benz\u00edlico<\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Ativador can\u00f4nico de AMPK de pequena mol\u00e9cula (mimetizador de AMP perme\u00e1vel \u00e0 c\u00e9lula via ZMP)<br \/>\n\u2705 Promove a capta\u00e7\u00e3o de glucose independente de insulina no m\u00fasculo esquel\u00e9tico<br \/>\n\u2705 Suprime a gliconeog\u00eanese hep\u00e1tica, lipog\u00eanese de novo e s\u00edntese de colesterol<br \/>\n\u2705 Fen\u00f3tipo publicado como \u2018mimetizador de exerc\u00edcio\u2019 (Narkar et al. 2008, Cell)<br \/>\n\u2705 Composto de refer\u00eancia para farmacologia de AMPK \u2014 PM 258.23, CAS 2627-69-2<\/p>\n<p><strong>AICAR<\/strong> contains 5-aminoimidazole-4-carboxamide-1-\u03b2-D-ribofuranoside compound.<\/p>","protected":false},"featured_media":71435,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6486,6487,6485,6488,6489,6484,6482],"class_list":["post-71431","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-acadesine","product_tag-aica-riboside","product_tag-aicar","product_tag-ampk-activator","product_tag-exercise-mimetic","product_tag-metabolic-research","product_tag-research-compound","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product\/71431","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/comments?post=71431"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media\/71435"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/media?parent=71431"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_brand?post=71431"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_cat?post=71431"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-br\/wp-json\/wp\/v2\/product_tag?post=71431"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}